Recombinant CA19-9 Antibody [CA19.9/1390R] | 34-073

Recombinant CA19-9 Antibody [CA19.9/1390R] | 34-073 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: Purified human protein used as the immunogen for the recombinant CA19-9 antibody.

Research Area: Cancer

Tested Application: WB, Flow, IF, IHC-P

Application: Flow Cytometry: 2-4 ug/million cells in 0.1ml
Immunofluorescence: 5-10 ug/ml
Immunohistochemistry (FFPE) : 5-10 ug/ml for 30 min at RT
Prediluted IHC only format: incubate for 30 min at RT (1)
Optimal dilution of the recombinant CA19-9 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein A affinity

Clonality: Recombinant Monoclonal

Clone: CA19.9/1390R

Isotype: IgG, k

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: N/A

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens.